The Economic Times

A pill that doubles survival: Revolution's FDA-approved drug gives pancreatic cancer patients a fighting chance

The US FDA has approved Revolution Medicines' pancreatic cancer drug Rasonque. This once-daily pill doubles survival for patients with advanced metastatic pancreatic cancer. Rasonque blocks the RAS protein, which drives tumor growth in many pancreatic cancers. Doctors hail this development as a significant breakthrough in cancer treatment. The drug is now available in the US, offering hope to many suffering patients.